For the millions of people using GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight, a familiar question hangs over every prescription refill: once the weight is off, do you have to stay on the highest dose forever? Two new clinical trials published in Nature Medicine and The Lancet suggest the answer may be no — and that the path forward could include lower, more tolerable doses that still hold the line on weight regain.
Why Maintenance Matters in GLP-1 Therapy
GLP-1 medications work by mimicking a gut hormone that slows stomach emptying, blunts appetite, and modulates reward pathways in the brain. They have transformed obesity care, with pivotal trials showing average weight reductions of 15% to 22% of body weight at high doses. But durability has been the field’s open question. Earlier research, including the well-known STEP 1 extension study, found that people who stopped semaglutide regained roughly two-thirds of their lost weight within a year, according to data published in Diabetes, Obesity and Metabolism.
That pattern has reinforced the view, echoed by the National Institutes of Health, that obesity behaves like a chronic disease requiring ongoing treatment rather than a short course of medication. The catch: high doses can be expensive, in short supply, and difficult to tolerate, with gastrointestinal side effects driving many people to discontinue therapy.
What the New Trials Found
The first study, known as ATTAIN-MAINTAIN and published in Nature Medicine, evaluated an investigational once-daily oral GLP-1 pill from Eli Lilly. Adults who had already lost significant weight on injectable medications were randomized to continue with the oral agent or to placebo for one year. Researchers reported that participants previously treated with semaglutide regained on average only about 0.9 kilograms (roughly 2 pounds), while those who had been on tirzepatide regained closer to 5 kilograms (about 11 pounds). Placebo groups regained substantially more.
The companion SURMOUNT-MAINTAIN trial, published in The Lancet, took a different approach: it asked whether people who reached their weight-loss plateau on the maximum tolerated dose of tirzepatide could step down to a lower 5-milligram weekly dose without losing ground. After roughly 60 weeks of high-dose induction, participants were randomized to stay at maximum dose or switch to the lower maintenance dose for one year. Those who continued at maximum dose preserved essentially all of their prior weight loss; those who stepped down to 5 milligrams retained most of it, with an average regain of about 5.6 kilograms.
A New Model: Induction, Then Maintenance
Taken together, the findings hint at a treatment model familiar in other chronic conditions — a higher-intensity induction phase to drive results, followed by a gentler maintenance phase to hold them. Mir Ali, MD, a bariatric surgeon at MemorialCare Surgical Weight Loss Center in Fountain Valley, California, commented to Medical News Today that the results align with what clinicians already see in practice: lower doses often sustain weight loss while improving tolerability.
The American Heart Association and the Obesity Medicine Association have both highlighted the need for evidence-based long-term strategies, since most people regain weight after discontinuation. A flexible maintenance dose could address several real-world barriers at once: cost, supply pressure, and the side effects that lead patients to stop treatment.
Side Effects and Who Discontinues
Gastrointestinal symptoms — nausea, constipation, diarrhea, and vomiting — remain the most common adverse effects of GLP-1 therapy and are cited in published trials as the leading reason people stop. The Food and Drug Administration’s labeling for semaglutide and tirzepatide includes warnings about pancreatitis, gallbladder disease, and, based on rodent studies, a potential risk of medullary thyroid carcinoma. Lower maintenance doses, if validated in larger and more diverse populations, could reduce the side-effect burden that currently drives discontinuation.
Researchers also note that GLP-1 therapy is associated with loss of lean muscle mass alongside fat loss. Maintenance strategies that pair lower drug doses with resistance training and adequate protein intake — generally 1.2 to 1.6 grams per kilogram of body weight per day, according to International Society of Sports Nutrition guidance — may help preserve muscle and metabolic health over time.
What to Watch Next
Several caveats apply. Both new trials were sponsored by Eli Lilly, which manufactures tirzepatide and the investigational oral agent. Independent replication will be important, particularly in older adults, people with type 2 diabetes, and participants from a broader range of ethnic backgrounds. The follow-up window — about one year — also leaves open how lower-dose maintenance performs over five or ten years, the realistic horizon for a chronic-disease model of obesity care.
Cost and access remain central questions. List prices for GLP-1 medications in the United States exceed $1,000 per month, and insurance coverage for obesity indications is uneven. A validated lower-dose maintenance regimen could meaningfully reduce annual expenses for patients who tolerate it, while freeing up high-dose supply for those still in the induction phase of therapy.
Practical Takeaways
For people currently on GLP-1 therapy, the new data should be discussed with a prescribing clinician rather than acted on independently. Dose changes — up or down — should be guided by individual response, side-effect profile, and overall health goals. Lifestyle factors that compound the benefits of pharmacotherapy continue to matter: research suggests that regular resistance training, a high-fiber Mediterranean-style eating pattern, adequate sleep, and stress management all contribute to durable weight maintenance.
For the broader field, the trials add to a growing recognition that obesity treatment is shifting from acute weight loss to long-term metabolic management. As the evidence base matures, patients and clinicians may have more options — and more flexibility — to make GLP-1 therapy sustainable for the years it may need to last.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.